Pfizer had been hoping the once-daily pill treatment would give it an edge over leading weight-loss treatments like Zepbound from Eli Lilly and Co. and Novo Nordisk’s Wegovy, which are injectable.
Weeks after ordering all Food and Drug Administration employees back into the office, the agency is allowing some of its most prized staffers to work remotely.
The drugmaker accuses Premier Weight Loss of risking patients’ health by selling altered, unsterile versions of its blockbuster drugs Mounjaro and Zepbound.
President Trump’s predecessor, Joe Biden, proposed a rule in late November after Trump won re-election that would have extended coverage of drugs like Zepbound and Wegovy.
Aside from building four new plants, Johnson & Johnson said that it will expand several existing sites.
Members of the Sackler family who own the OxyContin maker Purdue Pharma would hand over the company in the latest plan to settle thousands of lawsuits.
Indianapolis-based Eli Lilly and Co. launched LillyDirect a little more than a year ago and has been ramping up efforts to connect directly with consumers on the platform since.
Novo Nordisk’s new offering follows a direct-to-consumer model that Eli Lilly launched last year.
The results showed that the number of severe adverse events for patients was 54.3% higher than that of drugs made in emerging economies.
Supplies of high-demand obesity treatments are improving, but that doesn’t mean they’re easier to get.
The foundry will give the pharmaceutical maker the ability to research new ways of producing medicines.
President Donald Trump has instructed his administration to scrutinize the “threat” to children posed by antidepressants, stimulants and other common psychiatric drugs.
President Trump wasted little time turning to economic policy once his second term began, imposing or threatening to impose a barrage of tariffs on many of Indiana’s trading partners.
The results add to evidence from animal studies and reports that people are finding the drugs helpful to manage cravings, not just for food, but also for tobacco and alcohol.
The painkiller is the first novel pain drug to win government authorization in more than 20 years.
The deal represents an increase of more than $1 billion over a previous settlement deal that was rejected last year by the U.S. Supreme Court.
The research is the first to attempt to comprehensively investigate the impact—both good and bad—of the GLP-1 weight-loss drugs on the human body.
The lawsuit alleges the price increases EpiPen, used to treat severe allergic reactions, prevented other similar medications to from going to market.
The company expects fourth-quarter revenue to be about $13.5 billion.
The Indianapolis-based drugmaker will acquire Scorpion’s STX-478, a once-daily oral treatment in early trials for breast cancer and other advanced solid tumors.
